Piramal Pharma Limited (PPLPHARMA) — Net Asset Quality Index
Piramal Pharma Limited (PPLPHARMA) has a Net Asset Quality Index of 45.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Rs179.65 Billion minus total liabilities of Rs98.02 Billion yields net assets of Rs81.63 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Piramal Pharma Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Piramal Pharma Limited Net Asset Quality Index Over Time (2021–2026)
This chart shows how Piramal Pharma Limited's Net Asset Quality Index has evolved across 6 annual periods from 2021 to 2026. As of March 2026, the index stands at 45.4%, representing net assets of Rs81.63 Billion against total assets of Rs179.65 Billion INR. Explore PPLPHARMA cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Piramal Pharma Limited (2021–2026)
The table below presents the year-by-year Net Asset Quality Index for Piramal Pharma Limited from 2021 to 2026, covering 6 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Piramal Pharma Limited market capitalisation.
| Year | Quality Index | Net Assets (INR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2026 | 45.4% | Rs81.63 Billion | Rs179.65 Billion | Rs98.02 Billion | ▼ -6.4 pp |
| 2025 | 51.8% | Rs81.25 Billion | Rs156.78 Billion | Rs75.52 Billion | ▲ +0.2 pp |
| 2024 | 51.7% | Rs79.11 Billion | Rs153.12 Billion | Rs74.00 Billion | ▲ +5.0 pp |
| 2023 | 46.6% | Rs67.73 Billion | Rs145.23 Billion | Rs77.49 Billion | ▼ -5.7 pp |
| 2022 | 52.3% | Rs66.97 Billion | Rs127.97 Billion | Rs61.00 Billion | ▼ -18.9 pp |
| 2021 | 71.2% | Rs41.01 Billion | Rs57.57 Billion | Rs16.56 Billion | — |